SCHEMBL6607482

SCHEMBL6607482

CNC[C@@H](O)c1cccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.51
SLC6A2 P23975 4/20 0.51
SLC6A4 P31645 4/20 0.51
CYP3A4 P08684 3/20 0.51
CYP2D6 P10635 3/20 0.51
KCNH2 Q12809 2/20 0.51
HIF1A Q16665 4/20 0.44
KDM4E B2RXH2 4/20 0.44
BLM P54132 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
HTR1A P08908 2/20 0.44
ALDH1A1 P00352 2/20 0.44
THPO P40225 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NMUR2 Q9GZQ4 1/20 0.44
CYP2C9 P11712 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
ADRB1 P08588 3/20 0.43
ADRA2A P08913 3/20 0.43
ADRB3 P13945 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286627 1.00 SLC6A3 (0.51) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
SCHEMBL22593395 0.84 NPC1 (0.45) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
SCHEMBL14110183 0.81 SLC6A2 (0.56) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
SCHEMBL1201347 0.81 SLC6A2 (0.49) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
SCHEMBL98019 0.81 SLC6A2 (0.49) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
SCHEMBL165478 0.81 SLC6A2 (0.49) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
SCHEMBL18884424 0.81 AOC3 (0.50) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
Dimethylamine SCHEMBL27876905 0.81 NPC1 (0.43) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
Dimethylamine SCHEMBL27907968 0.79 KMT2A (0.42) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6
Methylamine SCHEMBL6327312 0.79 SLC6A2 (0.47) SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458719-A1 PYRIDOQUINOXALINE ANTIVIRALS PHARMACIA & UPJOHN COMPANY (US) 2004-09-22 EP claimed
US-20030207877-A1 Pyridoquinoxaline antivirals PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
WO-2003053971-A1 PYRIDOQUINOXALINE ANTIVIRALS PHARMACIA & UPJOHN COMPANY (US) 2003-07-03 WO claimed
EP-1458719-A1 PYRIDOQUINOXALINE ANTIVIRALS PHARMACIA & UPJOHN COMPANY (US) 2004-09-22 EP disclosed
US-20030207877-A1 Pyridoquinoxaline antivirals PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed
WO-2003053971-A1 PYRIDOQUINOXALINE ANTIVIRALS PHARMACIA & UPJOHN COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207877-A1 Pyridoquinoxaline antivirals IFNAR1, SARS1, ZC3HAV1 SLC6A3 464/4885SLC6A2 896/4885SLC6A4 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.